SUSAN DAUWALDER: Open Payments
NPI 1366409179 · NASHVILLE, TN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$798 in 42 payments from 11 companies in 2025. Trend: 2023 $679 · 2024 $522 · 2025 $798
Food & beverage: $798
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 14 | $271 |
| ABBVIE INC. | 6 | $130 |
| Vanda Pharmaceuticals Inc. | 5 | $91 |
| Axsome Therapeutics, Inc. | 4 | $69 |
| Otsuka America Pharmaceutical, Inc. | 3 | $55 |
| Tris Pharma Inc | 2 | $36 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $35 |
| Alkermes, Inc. | 2 | $34 |
| IDORSIA PHARMACEUTICALS US INC | 2 | $32 |
| Neurocrine BioSciences, Inc. | 1 | $26 |
Products named: CAPLYTA, VRAYLAR, FANAPT, Auvelity, REXULTI, Dyanavel XR, TRINTELLIX, LYBALVI.
Industry payments across TN — which companies pay providers there.
